Luminex Corp (LMNX)
We assign a fundamental rating of 3 out of 10 to LMNX. LMNX was compared to 58 industry peers in the Life Sciences Tools & Services industry. LMNX has a bad profitability rating. Also its financial health evaluation is rather negative. LMNX is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
LMNX had positive earnings in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.88% | ||
| ROE | 4.84% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.4% | ||
| PM (TTM) | 5.39% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
There is no outstanding debt for LMNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
LMNX has an Altman-Z score of 4.59. This indicates that LMNX is financially healthy and has little risk of bankruptcy at the moment.
LMNX has a Debt/Equity ratio of 0.52. This is a neutral value indicating LMNX is somewhat dependend on debt financing.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.59 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 8.37 indicates that LMNX has no problem at all paying its short term obligations.
LMNX has a Quick Ratio of 6.08. This indicates that LMNX is financially healthy and has no problem in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.37 | ||
| Quick Ratio | 6.08 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 563.64% over the past year.
LMNX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -18.61% yearly.
Looking at the last year, LMNX shows a very strong growth in Revenue. The Revenue has grown by 27.73%.
LMNX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.92% yearly.
EPS 1Y (TTM)563.64%
EPS 3Y-18.22%
EPS 5Y-18.61%
EPS growth Q2Q533.33%
Revenue 1Y (TTM)27.73%
Revenue growth 3Y10.83%
Revenue growth 5Y11.92%
Revenue growth Q2Q22.41%
3.2 Future
Based on estimates for the next years, LMNX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.43% on average per year.
The Revenue is expected to grow by 12.14% on average over the next years. This is quite good.
EPS Next Y159.95%
EPS Next 2Y78.43%
EPS Next 3Y72.36%
EPS Next 5Y50.43%
Revenue Next Year16.71%
Revenue Next 2Y12.52%
Revenue Next 3Y11.99%
Revenue Next 5Y12.14%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 72.53, the valuation of LMNX can be described as expensive.
The average S&P500 Price/Earnings ratio is at 24.55. LMNX is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 33.19, the valuation of LMNX can be described as expensive.
Compared to an average S&P500 Price/Forward Earnings ratio of 20.92, LMNX is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72.53 | ||
| Fwd PE | 33.19 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 18.82 |
4.3 Compensation for Growth
LMNX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as LMNX's earnings are expected to grow with 72.36% in the coming years.
PEG (NY)0.45
PEG (5Y)N/A
EPS Next 2Y78.43%
EPS Next 3Y72.36%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.08%, LMNX has a reasonable but not impressive dividend return.
Compared to an average S&P500 Dividend Yield of 2.39, LMNX's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
5.2 History
On average, the dividend of LMNX grows each year by 13.62%, which is quite nice.
LMNX has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)13.62%
Div Incr YearsN/A
Div Non Decr YearsN/A
5.3 Sustainability
LMNX pays out 72.38% of its income as dividend. This is not a sustainable payout ratio.
LMNX's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP72.38%
EPS Next 2Y78.43%
EPS Next 3Y72.36%
Luminex Corp
NASDAQ:LMNX (7/13/2021, 7:00:00 PM)
After market: 37 +0.01 (+0.03%)36.99
+0.01 (+0.03%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.75B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.08% |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 72.53 | ||
| Fwd PE | 33.19 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.45
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.88% | ||
| ROE | 4.84% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 12.4% | ||
| PM (TTM) | 5.39% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 8.37 | ||
| Quick Ratio | 6.08 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)563.64%
EPS 3Y-18.22%
EPS 5Y
EPS growth Q2Q
EPS Next Y159.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)27.73%
Revenue growth 3Y10.83%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y